Type 2 Diabetes Mellitus (T2DM) is one of the most prevalent endocrine disorders underlining the importance of developing molecular therapies to mitigate T2DM.1 It is characterized by a significant decrease in β-cell mass, insulin resistance and presence of amyloid plaques2 in which human islet amyloid polypeptide (hIAPP) is the major protein component.3 hIAPP is a 37-residue polypeptide co-secreted with insulin in β-cells of islets of Langerhans. This evidence concerns the gene IAPP and type 2 diabetes mellitus.